Borderline personality disorder (BPD) occurs in 10-30% of patients with major depressive disorder (MDD), and over 80% of individuals with BPD also have MDD. This comorbidity leads to more severe depression, greater functional impairment, higher treatment resistance, and increased suicidality. While ketamine effectively treats treatment-resistant depression (TRD), existing studies often did not exclude people with BPD, suggesting benefits may extend to those with both conditions. However, no protocols specifically address this comorbidity, and psychotherapeutic interventions crucial for lasting effects have been omitted.
A corrigendum corrects errors in a previously published article on transcranial magnetic stimulation and ketamine for depression. The original funding statement displayed an incorrect grant number; the correct number is "Key Development Project of Department of Science and Technology (2015C03Bd051)." Additionally, the original Conflict of Interest statement omitted that two co-authors were employed by KeyClinic, a commercial mental health center offering ketamine and TMS treatment among other services, and one author was employed by Mind Health, served on the Janssen Cilag Advisory Board, and gave lectures for Janssen Cilag.